Aarti Pharmalabs Limited has initiated the Second 100-Day Campaign 'Saksham Niveshak' following a directive from the Investor Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs, dated March 27, 2026. The campaign, running from April 01 to July 09, 2026, aims to facilitate the settlement of unpaid and unclaimed dividends while creating awareness among shareholders.

Campaign Overview and Purpose

The aarti pharma labs initiative focuses on proactive shareholder engagement by updating essential records, expediting dividend processing, preventing unwarranted share transfers to the IEPFA, and facilitating direct settlement of claims by the company. The campaign serves as a crucial opportunity for shareholders to claim their outstanding dividends before these amounts are transferred to the Investor Education and Protection Fund.

Required Documentation and Process

Shareholders must update several key details to claim their unpaid dividends:

Since dividends are payable only through electronic mode, amounts will be credited to shareholders' bank accounts only after the required information and documents are updated. Shareholders can download necessary documents from the designated portal provided by MUFG Intime India Private Limited.

Electronic and Physical Share Holdings

Shareholders holding shares in electronic form who have not claimed their dividends can do so by updating or modifying their details with their respective Depository Participants (DPs). The company will send letters and emails to applicable shareholders mentioning details about unpaid dividends along with the claiming process. Details of unclaimed and unpaid dividends have been uploaded on the company's website.

Important Deadlines and Consequences

Shareholders must submit their documents by July 09, 2026, to support the campaign's success. The company has emphasized that dividend amounts remaining unclaimed for seven consecutive years will result in the corresponding equity shares being transferred to the IEPF Authority in accordance with Ministry of Corporate Affairs notifications.

Support and Assistance

For shareholders requiring assistance during the campaign, the company has provided multiple contact channels:

• Company Contact: investorrelations@aartipharmalabs.com
• Registrar Contact: rnt.helpdesk@in.mpms.mufg.com
• Company Website: https://www.aartipharmalabs.com/
• RTA Website: www.in.mpms.mufg.com

Shareholders whose unclaimed dividends or shares have already been transferred to IEPF can submit the prescribed Form IEPF-5 online and send physical documents to the company or registrar as per the process outlined on the IEPF website. The campaign represents a significant opportunity for shareholders to regularize their holdings and claim outstanding benefits before the July deadline.

Aarti pharma labs promoter Mr. Mirik Rajendra Gogri has disclosed the creation of a pledge on company shares under SEBI regulations. The disclosure, submitted on March 31, 2026, pertains to the pledging of shares for personal borrowing purposes under Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Details and Structure

The pledge involves 27,84,094 shares of Aarti Pharmalabs Limited, representing 3.08% of the company's total share capital. The encumbrance was created on March 25, 2026, in favor of two financial entities for third party pledge purposes.

Beneficiary Entities and Distribution

The pledged shares have been distributed between two financial institutions. Bajaj Financial Securities Limited received the larger portion with 26,16,700 shares, while 360 One Distribution Services Limited received 1,67,394 shares.

Financial Terms and Security Cover

The borrowing arrangement involves ₹75,00,00,000 against the pledged shares valued at ₹177,90,36,066 on the agreement date. This provides substantial security coverage for the lenders with a security cover ratio of 2.37.

Promoter Shareholding Context

As of December 31, 2025, Mr. Mirik Rajendra Gogri held 3,90,66,368 shares representing 43.10% of Aarti Pharmalabs Limited's total share capital. The current pledge represents 7% of his total promoter shareholding, which falls below the significant threshold levels requiring additional regulatory scrutiny.

The disclosure confirms that both beneficiary entities are recognized financial institutions, and the encumbrance is not related to any debt instruments such as debentures or commercial papers. The pledge arrangement follows standard regulatory compliance requirements under SEBI regulations for substantial acquisition of shares and takeovers.